Retension Pharmaceuticals, Inc.

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hypertension and other cardiovascular diseases. The company aims to address the significant unmet need for effective therapies for patients whose blood pressure remains uncontrolled despite existing medications. Its lead product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (PDE-5) inhibitor. RTN-001 is designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism in hypertension. Unlike first-generation PDE-5 inhibitors, RTN-001 was engineered using a proprietary surface chemistry-driven platform to enhance its bioavailability and distribution to cardiovascular smooth muscle tissues in the central vasculature. This design aims to achieve more consistent and sustained blood pressure reduction. Retension Pharmaceuticals is currently evaluating RTN-001 in a Phase 2b clinical trial, which began in October 2025, with initial data anticipated in the first half of 2027. Earlier Phase 2 pilot trials demonstrated that RTN-001 was well-tolerated and showed clinically significant blood pressure-lowering effects in patients with uncontrolled hypertension. The company's business model involves conducting clinical trials, securing regulatory approvals, and potentially partnering with pharmaceutical companies for distribution and marketing. Retension Pharmaceuticals was founded in 2023 and is headquartered in Falls Church, United States. Sources: [1] https://pitchbook.com/profiles/company/638631-19 [2] https://www.retensionpharmaceuticals.com/about [3] https://www.retensionpharmaceuticals.com/ [4] https://dealroom.co/companies/retension-pharmaceuticals/ [5] https://www.tradingview.com/news/tradingview:ff2e24c534b45:0-retension-pharmaceuticals-clinical-stage-biopharma-for-hypertension-files-for-nasdaq-capital-market-ipo/ [6] https://www.renaissancecapital.com/Profile/RTSN/Retension-Pharmaceuticals/IPO [7] https://www.renaissancecapital.com/IPO-Center/News/122048/hypertension-drug-developer-retension-pharmaceuticals-sets-terms-for-40 [8] https://www.ipox.com/ipo-calendar/retension-pharmaceuticals [9] https://www.retensionpharmaceuticals.com/august212024